A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

To be part of this study, you would generally need to have bladder cancer that has spread (metastatic) or is locally advanced. Doctors would also need a recent tissue sample from your cancer to help them understand more about it.

For the first part of this study, you must have already had chemotherapy treatment that included platinum-based drugs for your advanced bladder cancer. Also, you should not have had more than two types of treatment for your advanced cancer before joining. If you had platinum-based chemotherapy followed by a maintenance drug called avelumab, that counts as two treatments.

There are also some reasons why you might not be able to join. For example, if you have other active cancers, certain severe heart problems, nerve damage (peripheral neuropathy) above a certain level, or specific eye conditions that could be affected by the study drugs.

If you join this study, you will receive the experimental treatments. You'll have regular visits to the clinic for assessments, which will likely include physical exams, blood tests, and scans to monitor your health and how the treatment is affecting your cancer. The specific schedule and duration of treatment and follow-up will depend on the study's protocol and your individual response. The total time you spend in the study will vary, but usually involves treatment cycles and then a period of follow-up care to track your progress and long-term health. You'll be closely monitored by the study team throughout.